NICE recommends the tablets for adults with moderate to severe fibroid symptoms. Linzagolix is recommended for longer-term ...

Innovative AI technologies have the potential to act like a ‘second pair of eyes’, helping radiologists review prostate MRI ...

From blood-based biomarkers to AI-powered tools, discover how 9 innovations are being tested in the NHS to speed up dementia ...

Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043] ...

This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It ...

This guideline covers support for disabled children and young people with severe complex needs, from birth to 25 years. It aims to encourage education, health and social care services to work together ...

There are commercial access agreements for encorafenib and binimetinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

This guidance has been updated and replaced by NICE's technology appraisal guidance on trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more lines ...

intermittently scanned continuous glucose monitoring. HCL systems are only recommended if they are procured at a cost-effective price agreed by the companies and NHS England, and implemented following ...

This guidance has been updated and replaced by NICE technology appraisal guidance 736 ...

Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch ...

There is a simple discount patient access scheme for zanidatamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...